NTRK2 and neoplasm: Unlike entrectinib which is a multikinase inhibitor that targets TrkA, TrkB, TrkC, ROS1 and ALK1, larotrectinib is a selective pan-Trk inhibitor, being the first oral “tumor-agnostic” treatment and the first developed simultaneously for both adults and children [[15], [16], [17]].